BetterLife Pharma(OTC) BETRF

Market Cap$33.61M

Since IPO (2010)-100%

5 Year-6%

1 Year+239%

1 Month+46%

$0.20

-2.07%

-0.00Today

BetterLife Pharma last closing stock price
Metric	Price	Date
Last close	USD 0.21	2026-08-13

BetterLife Pharma stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-26.46%	USD 0.28	2026-08-06
1 month	+45.79%	USD 0.14	2026-07-14
3 month	+323.67%	USD 0.05	2026-05-15
Year to date	+542.72%	USD 0.03	2025-12-31
1 year	+239.22%	USD 0.06	2025-08-12
3 year	+274.05%	USD 0.06	2023-08-11
5 year	-5.59%	USD 0.22	2021-08-13
Since inception	-99.92%	USD 252.00	2010-10-04

BetterLife Pharma Financials at a Glance

Market Cap

$33.61M

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$1.89M

EPS (TTM)

-$0.01

P/E Ratio

-23.07

Dividend

$0.00

Beta (Volatility)

0.32 (Low)

Dividend

$0.00

Beta (Volatility)

0.32 (Low)

Price

$0.20

Volume

87,146

Open

$0.23

Price

$0.20

Volume

87,146

Open

$0.23

Previous Close

$0.20

Daily Range

$0.19 - $0.24

52-Week Range

$0.03 - $0.33

Estimated Earnings Date

Jun 26, 2026

Dividend

$0.00

Beta (Volatility)

0.32 (Low)

Price

$0.20

Volume

87,146

Open

$0.23

Previous Close

$0.20

Daily Range

$0.19 - $0.24

52-Week Range

$0.03 - $0.33

Estimated Earnings Date

Jun 26, 2026

BETRF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BetterLife Pharma

BetterLife Pharma Inc. is a biotechnology firm based in Vancouver, Canada, focused on developing therapeutic compounds for neurological disorders. The company specializes in interferon-based technologies aimed at enhancing the immune response against viral infections.

Products and Services

BETR-001 targets major depressive disorder and PTSD
BETR-002 is developed for benzodiazepine dependency and anxiety
MM-003 focuses on COVID-19 and respiratory viral infections

Growth Outlook

Strong pipeline with multiple drug candidates in various stages of development
Collaboration with UC San Diego enhances research capabilities
Potential market expansion as neurological disorders increase globally

Financial Highlights

Recent quarterly net income of -$609,054 reflects ongoing R&D investments
Trailing twelve months (TTM) revenue remains at $0, indicating early-stage development
Cash and cash equivalents increased to $28,566 in the latest quarter

AI Generated • Jul 29, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Ahmad Doroudian, PhD

Website

www.abetterlifepharma.com

Headquarters

Vancouver, BC V6H 1A6, CA

BETRF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

19.88%

Return on Capital

N/A

Return on Assets

-780.97%

Earnings Yield

-4.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$33.61M

Shares Outstanding

161.89M

Volume

87.15K

Avg. Volume

136.84K

Financials (TTM)

Gross Profit

CA$0.00

Operating Income

-CA$1.91M

EBITDA

-CA$1.84M

Operating Cash Flow

-CA$851.03K

Capital Expenditure

-CA$3.00

Free Cash Flow

-CA$851.03K

Cash & ST Invst.

CA$28.57K

Total Debt

CA$617.30K

BetterLife Pharma Performance Analysis

BetterLife Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2023	2023-01-31	CAD 0	N/A
2024	2024-01-31	CAD 0	N/A
2025	2025-01-31	CAD 0	N/A
2026	2026-01-31	CAD 0	N/A

BetterLife Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-07-31	N/A
Q3	2025-10-31	N/A
Q4	2026-01-31	N/A
Q1	2026-04-30	N/A

BetterLife Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2023	2023-01-31	CAD -0.08	-38.1%
2024	2024-01-31	CAD -0.02	-75.4%
2025	2025-01-31	CAD -0.02	5.1%
2026	2026-01-31	CAD -0.01	-64.1%

BetterLife Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-07-31	-106.3%
Q3	2025-10-31	18.2%
Q4	2026-01-31	7.4%
Q1	2026-04-30	-56.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2027YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

CA$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$33.61M

N/A

Market Cap/Employee

$4.80M

N/A

Employees

N/A

Net Income

-CA$609.05K

-188.0%

EBITDA

-CA$561.21K

-331.9%

Quarterly Fundamentals

Name

Q1 2027YOY CHG

Total Cash

CA$28.57K

+50.4%

Total Debt

CA$617.30K

-52.7%

Accounts Receivable

CA$7.97K

-2.8%

Inventory

CA$0.00

N/A

Long Term Debt

CA$27.67K

-46.0%

Short Term Debt

CA$589.64K

-52.9%

Return on Assets

-7.81%

N/A

Return on Invested Capital

29.80%

N/A

Free Cash Flow

-CA$239.15K

-1578.8%

Operating Cash Flow

-CA$239.15K

-1578.8%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

TXTMProText Mobility, Inc.

TXTMProText Mobility, Inc.$0.00+5.41%

CUBTCurative Biotechnology, Inc.

CUBTCurative Biotechnology, Inc.$0.97+4.64%

PHRRFPharmaTher Holdings Ltd.

PHRRFPharmaTher Holdings Ltd.$0.04+12.37%

BIXTBioxytran, Inc.

BIXTBioxytran, Inc.$0.02-15.66%

BZYRBurzynski Research Institute, Inc.

BZYRBurzynski Research Institute, Inc.$0.01+0.00%

CPMVMosaic ImmunoEngineering Inc.

CPMVMosaic ImmunoEngineering Inc.$0.06-87.80%

NSHSFNanoSphere Health Sciences Inc.

NSHSFNanoSphere Health Sciences Inc.$0.01+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NUNu Holdings

NUNu Holdings$15.23+0.09%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$8.76+0.01%

ONDSOndas

ONDSOndas$9.24+0.04%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$140.00-0.01%

INTCIntel

INTCIntel$102.50-0.02%

NVDANvidia

NVDANvidia$225.16-0.00%

NOKNokia

NOKNokia$10.76+0.02%

Questions About BETRF

What is the current price of BetterLife Pharma?

BetterLife Pharma is trading at $0.20 per share.

What is the 52-week range for BetterLife Pharma?

Over the past 52 weeks, BetterLife Pharma has traded between $0.03 and $0.33.

How much debt does BetterLife Pharma have?

As of the most recent reporting period, BetterLife Pharma reported total debt of CA$453.68K.

How much cash does BetterLife Pharma have on hand?

BetterLife Pharma reported CA$20.99K in cash and cash equivalents in its most recent financial results.

What is BetterLife Pharma’s dividend yield?

BetterLife Pharma does not currently have a dividend yield.

BetterLife Pharma(OTC) BETRF

BetterLife Pharma Financials at a Glance

BETRF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About BetterLife Pharma

BETRF Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

BetterLife Pharma Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About BETRF

What is the current price of BetterLife Pharma?

What is the 52-week range for BetterLife Pharma?

How much debt does BetterLife Pharma have?

How much cash does BetterLife Pharma have on hand?

What is BetterLife Pharma’s dividend yield?

Premium Investing Services